Stock Forecast

  Allarity Therapeutics, Inc. ( ALLR) Stock. Should you Buy or Sell?    $ 1.17

-0.13 (-12.50 %)

Allarity Therapeutics, Inc. Analysis

Updated on 10-09-2022
Symbol ALLR
Price $1.17
Beta -0.003
Volume Avg. $294.85 thousand
Market Cap $11.63 M
52 Week Range $1.01 - $18.2

Allarity Therapeutics, Inc. opened the day at $1.17 which is -12.50 % on yesterday's close. Allarity Therapeutics, Inc. has a 52 week high of $18.2 and 52 week low of $1.01, which is a difference of $17.19. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $11.63 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Allarity Therapeutics, Inc. for $11.63 M, it would take 15 years to get your money back. Allarity Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Allarity Therapeutics, Inc. Stock Forecast - Is Allarity Therapeutics, Inc. a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreStrong Sell
ROA ScoreSell
DE ScoreBuy
PE ScoreSell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value

PE Ratio -0.997
Dividend Yiel 0.000
Net Profit Margin 0.000

Valuing Allarity Therapeutics, Inc.

Price Book Value Ratio 0.658 Price To Book Ratio 0.658
Price To Sales Ratio 0.000 Price Earnings Ratio -0.997

How liquid is Allarity Therapeutics, Inc.

Current Ratio 1.354
Quick Ratio 1.144


Debt Ratio 0.461 Debt Equity Ratio 0.979
Long Term Debt To Capitalization 0.000 Total Debt To Capitalization 0.000

Latest news about Allarity Therapeutics, Inc.

Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR

Are these penny stocks to buy or avoid right now? The post Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR appeared first on Penny Stocks to Buy, Picks, News and Information |

Date : 27/05/2022

About Allarity Therapeutics, Inc.

Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : NASDAQ Global Market

Description :

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

My Newsletter

Sign Up For Updates & Newsletters